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Background 
Human T Iymphotropic virus type I (HTLV- I )-associated myelopathy/troplcal spas-
tic paraparesls (HAM/TSP) is a chronic inflammatory myelopathy caused by HTLV- I 
infection. Although the pathogenesis of HAM/TSP is not fully understood, high HTLV-
l proviral loads and abnorma] immune responses have been suggested to play a pivotal 
role. The immunologic derangements include an increase of helper inducer T cells and 
activated T cells, and an abnormal up-regulation of T helper (Th) I cell responses. 
Hlstopathological studies in HAM/TSP have demonstrated that the infiltratlon of CD 
4+ and CD8+cells In the spinal cord lesions. Meanwhile, nature killer (NK) cells, which 
are important in the defense against virus-infected cells, are decreased in the peripheral 
blood (PB) in HAM/TSP. These lymphocyte subsets may contribute to the development 
of the inflammatory myelopathy. 
Interferon (lFN)-a has both antiviral and immunomodulatory actions. Some clini-
cal studies demonstrated that IFN-a is therapeutical]y effective in HA~~/TSP. Previous 
immunological analysis of IFN-a in HA~/1/TSP showed a suppressed spontaneous prolif-
eration of PB, an increase in CD8+DR+T cells and elevated serum soluble IL-2 receptor 
levels, and a decrease in the CD4/CD8 ratio in PB. Detailed lymphocyte subsets includ-
ing Th 1/Th 2 cells, NK and NKT cell-:~ in the cerebrospina] fluid (CSF) and PB in 
HA~/1/TSP patients treated with IFN-a have never been analyzed. 
There are some pieces of evidence that HTLV- I proviral loacl relates to the develop-
ment, or_set, and progression of the disease, but effects of IFN-a on the HTLV- I 
proviral load in HAM/TSP have not been investigated with real-time PCR. 
Objective 
To investigate the immunological and virological consequences of the IFN-a thelapy 
in HAIVI/TSP. 
MethodS 
Nine HAM/TSP patients (5 wcuTlen and 4 men ; age range 54~72 years) were analyzed 
in the study. They received intramuscular injections of IFN-a 3 mlllion units daily for 
4 weeks, and clinical and laboratory assessments were done as follows. The motor disabil-
ity and dysunia of the patients was graded according to the Osame's disability scale. We 
determined the serum neopterine levels, a marker of the biological activity of IFN-a . 
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With flow cytom)'ter, we studied T, NK, NKT cell subsets and Thl and Th2 associated 
chemokine receptor expression on T cells in CSF as ¥~'ell as PB of the patie.nts treated 
¥~'ith IFN-a. Meanwhile, the intracellular cytoklnes (IFN-7 and IL-4) of T cells in PB 
were also analyzed. In addition, we also measured the HTLV- I proviral loads in PBMC 
using a real-time PCR assay for HTLV- I tax. Finally, we ccuTlpared immunological and 
viro]ogical data in "responders" and "non-responders" to the IFN-a therapy. 
ReSUltS 
After the therapy, we obtained the following findings. The motor disability was re-
lie¥'ed in 3 out of 9 patients. The serum neopterine levels were significantly increased. 
The CD4/CD8 ratio in CSF was signlficantl3, Iower, ¥ivhich is mainly attributable to the 
significant reduction in CD4+cells, especlall3, CD25~-CD4 and CD45R0+CD4 cell sub-
sets. Meanwhile, NI(, natural T and NKT cell subsets In CSF remained unchanged. The 
percentages of CCR5+cells in CD4+cells signlflcantly decrease.d in both CSF and PB. A 
significant reduction of the ratio of IFN-?' +cells to inter'leukin (IL)-4+cells among 
CD3+cells (IFN-7+ IL-4+ in T ce]Is) was also observed in PB. HTLV- I proviral loads 
decreased in the 3 patients with 2xlOi copies or more in 10~ pB mononuclear cells in 
whom a definite suppression of IFN- 7 + IL-4+ in T cells and clinical improvement were 
observed. Before therapy, the CD4+, CD4+cCR5+, CD4+CD25+, CD4+CD45R0+ 
and CD4+CD29+cell subsets in the CSF and blood and the CD8~cell subset in CSF 
and the proviral loads had a tendency to be higher in responders than in non-responders. 
After therapy, there was a tendency for such CD4 subsets as well as the proviral loads 
to decrease evidently in resl)onders as compared with those in non-responders. 
ConcIUSion 
The present study demonstrated that IFN-a therapy inhibited. the infiltratlon of the 
CD4-~ T cell subsets into the central nervous system in HAM/TSP. The therap~' also 
suppessed Thl resr)onses in CSF and PB. These Immunological changes may relate to 
the alleviation of inflammation within the spina] cord. Moreover, we showed a decrease 
in the HTLV- I copy numbers in PB following the therapy in patients with higher 
proviral loads, in whom a suppression of Th I responses and clinical improvement were 
observed and thus the Immunological changes induced b3, IFN- a in IIAM/TSP are 
probably closely associated with the proviral loads. 
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Human T Iymphotropic virus type I (HTLV- I )-associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP) is a chr'onic inflammatory myelopathy caused by HTLV- I 
infection. Although the pathogenesis of HAM/TSP is not fully understood, high HTLV-
I proviral loads and abnormal immune responses have been suggested to play a pivota 
role. Some clinical studies demonstrated that interferon (IFN)-a is therapeutically effec-
tive in HAM/TSP. However, detailed lymphocyte subsets Includlng Th 1/Th 2 cells, NK 
and NKT ce]Is in the cerebrospinal fluid (CSF) and PB in HAM/TSP patients treated 
with IFN-a have never been analyzed. We herein investigate the immunological and 
virological consequences of the IFN-a therapy in HAM/TSP. 
Nine HAM/TSP patients (5 women and 4 men ; age range 54-72 years) were analyzed 
in the study. They received intramuscular injections of IFN-a 3 million units daily for 
4 weeks, and clinical and laboratory assessments were done as follow. With flow 
cytomyter, we studied T, NK, NKT cell subsets and Th I and Th 2 associated chemokine 
receptor expression on T cells in CSF as well as PB of the patients treated with IFN-
a . We also measured the HTLV- I proviral loads in PBMC using a real-time PCR assay 
for HTLV- I tax. Finally, we compared immunological and virological data in "respond-
ers" and "non-responders" to the IFN-a therapy. 
After the therapy, the motor disability was relieved in 3 out of 9 patients. The 
serum neopterine levels were significantly increased. The CD4/CD8 ratio in CSF was 
significantly lower, which is malnly attributable to the significant reduction in CD4+ cells, 
especially CD25+CD4 and CD45R0+CD4 cell subsets. Meanwhile, NK, natural T and 
NKT cell subsets in CSF rerr!_ained unchanged. The percentages of CCR 5+ cells in CD 4 + cells 
significantly decreased in both CSF and PB. HTLV- I proviral loads decreased in the 3 
patients with 2xlO~ copies or more in 105 PB mononuclear cells in whom a definite sup-
pression of IFN- 7 +T/IL-4+ in T cells and clinical improvement were observed. Before 
therapy, the CD4+, CD4+CCR5+, CD4+CD25+, CD4+CD45R0+ and CD4+CD29+ 
cell subsets in the CSF and blood and the CD8+cell subset in CSF and the proviral loads 
had a tendency to be higher in responders than in non-responders. After therapy, there 
was a tendency for such CD4 subsets as well as the proviral loads to decrease evidently 
in responders as compared with non-responders. 
The present study demonstrated that IFN- a therapy inhibited the infiltration of 
the CD4+ T cell subsets into the central nervous system in HAM/TSP. The therapy 
also suppressed Thl responses in CSF and PB. These immunological changes may relate 
to the alleviation of inflammation within the spinal cord. Moreover, we showed a de-
crease in the HTLV- I copy numbers in PB following the therapy in patients with 
higher proviral loads, in whom a suppression of Th I responses and clinical improvement 
were obsei'ved and thus the immunological changes induced by IFN- a in HAM/TSP are 
probably closely associated with the proviral loads. 
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